Skip to main content
OpenTrials
Completed

NCT Number: NCT02621554

Impact of Resveratrol on Brain Function and Structure

The study will investigate whether resveratrol could provide positive effects on memory and brain structures and functions in healthy elderly participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences

Leipzig, Germany

About this study

Cell and animal studies postulated various beneficial effects of resveratrol, ranging from a reduction of inflammatory processes and the treatment of cancer to the prevention of cardiovascular diseases and stroke. With regard to cognitive decline, rodent models for Alzheimer's disease (AD) showed improved learning and decelerated hippocampal neurodegeneration after intake of resveratrol.

Animal and first human studies provided evidence that resveratrol might serve as an easy, cost-effective option to develop novel prevention and treatment strategies against age-associated cognitive decline. To test this hypothesis, the researchers study general brain structure and function on healthy older individuals (> 60years old).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjects who are healthy or with subjective memory complaints
  • older than 60 years old
  • normal to overweight participants (BMI: 22-40 kg/sqm)

Exclusion criteria

  • dementia
  • Psychiatric diseases
  • severe untreated internal diseases
  • diabetes
  • younger than 60 years
  • BMI < 22 or >40

Treatment and study plan

Resveratrol Supplementation

Dietary Supplement

6 months of resveratrol supplementation

Placebo

Dietary Supplement

6 months of placebo intake

Primary outcomes

  1. Change from baseline Verbal Learning Task Scores at 6 months

    Time frame: Baseline (timepoint 0), after 6 months (timepoint 6 months)

Secondary outcomes

  1. Change from baseline Verbal Learning Task Scores at 12 months

    Time frame: after 12 months (timepoint 12 months)

  2. Mini Mental State Examination

    Time frame: Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)

  3. Structural changes on the brain MRI images

    Time frame: Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)

  4. Functional changes on the brain MRI images

    Time frame: Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)

  5. Plasma biomarkers

    Time frame: Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)

Sponsors and collaborators

Lead sponsor

Max Planck Institute for Human Cognitive and Brain Sciences

Other

Collaborators

  • Evolva SA
  • University of Leipzig

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Dec 3, 2015
Registry last updated
Feb 8, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.